GLP-1 medicines are facing renewed scrutiny over a possible link with a rare eye condition that can cause vision loss, as clinical data, regulatory reviews and litigation examine the potential risk.
Danish drugmaker Novo, formerly Novo Nordisk, said on Friday that data from its own clinical trials had recorded cases of non-arteritic anterior ischemic optic neuropathy (NAION) among people taking its GLP-1 medicines.
The development follows studies based on real-world patient records that have reported an association between semaglutide and NAION. European regulators have also classified NAION as a very rare side effect of semaglutide.
The issue is additionally being examined through litigation in the United States involving Novo and Eli Lilly, another major maker of GLP-1 medicines.
GLP-1 drugs have gained widespread attention for their use in diabetes treatment and weight management. The emerging safety discussions around NAION are now adding another area of scrutiny for the rapidly expanding drug category.
The available findings concern a possible association and do not, by themselves, establish that GLP-1 medicines cause the eye condition. Ongoing research, regulatory assessments and legal proceedings are expected to provide further clarity on the potential risk.
0 comments
No comments yet. Yours would be the first.